Balance Sheet
Cash Flow Statement
AcquisitionsAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Dividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Usana Health Sciences (USNA) Free Cash Flow (2016 - 2026)

Usana Health Sciences (USNA) has disclosed Free Cash Flow for 15 consecutive years, with -$12.9 million as the latest value for Q3 2025.

  • On a quarterly basis, Free Cash Flow fell 160.63% to -$12.9 million in Q3 2025 year-over-year; TTM through Sep 2025 was $18.7 million, a 71.52% decrease, with the full-year FY2024 number at $50.9 million, down 9.31% from a year prior.
  • Free Cash Flow was -$12.9 million for Q3 2025 at Usana Health Sciences, down from $12.2 million in the prior quarter.
  • In the past five years, Free Cash Flow ranged from a high of $30.3 million in Q4 2022 to a low of -$12.9 million in Q3 2025.
  • A 5-year average of $14.3 million and a median of $14.5 million in 2024 define the central range for Free Cash Flow.
  • Peak YoY movement for Free Cash Flow: surged 230.61% in 2022, then tumbled 160.63% in 2025.
  • Usana Health Sciences' Free Cash Flow stood at $18.1 million in 2021, then surged by 67.57% to $30.3 million in 2022, then crashed by 38.22% to $18.7 million in 2023, then plummeted by 78.7% to $4.0 million in 2024, then tumbled by 424.53% to -$12.9 million in 2025.
  • Per Business Quant, the three most recent readings for USNA's Free Cash Flow are -$12.9 million (Q3 2025), $12.2 million (Q2 2025), and $15.5 million (Q1 2025).